Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings

On Thursday, U.S. equity markets posted broad-based gains, with the S&P 500 rising 1.06% to 7,747.71, the Nasdaq Composite advancing 1.40% to 26,584.06, and the Dow Jones Industrial Average climbing 1.18% to 53,686.11, as risk appetite improved across the board.

Against this backdrop, ARK Invest's trading activity on the day appeared to reflect a selective "offense-with-discipline" approach — using the broad market rally as a window to add to a high-conviction disruptive innovation holding while trimming a peripheral position to optimize portfolio allocation.

Buy: Doubling Down on Precision Medicine with a CRISPR Core Holding

ARK added 39,548 shares of $Intellia Therapeutics (NTLA.US)$. Intellia is one of ARK's long-standing core positions in the in vivo CRISPR gene editing space, with a robust CRISPR/Cas9 platform that arguably provides a meaningful competitive moat in the treatment of hereditary diseases. The decision to increase exposure during a market-wide rally may suggest that ARK continues to hold strong conviction in Intellia's pipeline progress and long-term valuation re-rating potential.

Sell: Portfolio Rebalancing, Reducing a Non-Core Small-Cap Position

ARK sold 10,853 shares of $Brera Holdings (SLMT.US)$. Relative to the core disruptive innovation themes that define ARK's flagship funds, Brera Holdings occupies a more peripheral role in the portfolio. This reduction may reflect routine position rebalancing or a reallocation of capital toward higher-conviction thematic exposures. Releasing liquidity from non-core holdings during a strong tape to reinvest in primary themes is consistent with ARK's typical portfolio optimization discipline.

Not sure what to buy? Let the concentrated portfolios of top investors be your guide. This page aggregates high-conviction ideas from the world's best.

108K Views